新型非选择性β受体阻滞剂卡维地洛治疗门静脉高压症的研究进展

肝脏 ›› 2024, Vol. 29 ›› Issue (3): 345-347.

新型非选择性β受体阻滞剂卡维地洛治疗门静脉高压症的研究进展

陈治莉, 谢青, 莫瑞东

200025 上海交通大学医学院附属瑞金医院感染科(陈治莉,谢青,莫瑞东);610066 四川成都市公共卫生临床医疗中心肝病一科(陈治莉)

收稿日期:2023-06-18 出版日期:2024-03-31 发布日期:2024-05-16
通讯作者: 莫瑞东,Email:moruidong626@126.com
基金资助:
上海市临床重点专科(感染病学)(shslczdzk01103);国家自然科学基金(82070604,82270618);“十三五”科技部重大专项 (2017ZX10203201-008, 2018ZX09201016-003-001, 2017ZX10202202-005-004)

Received:2023-06-18 Online:2024-03-31 Published:2024-05-16

摘要/Abstract

摘要： 门静脉高压症(PH)是肝硬化最常见的并发症,也是肝硬化失代偿的主要驱动因素。卡维地洛作为新型非选择性β受体阻滞剂(NSBB), 较传统NSBB治疗肝硬化PH更有优势,有望作为治疗临床显著性门静脉高压(CSPH)的首选药物。与普萘洛尔和(或)食管静脉曲张套扎术 (EVL)相比,卡维地洛在血流动力学应答及静脉曲张破裂出血的一级和二级预防中,均体现出更好的疗效;在全身血流动力学稳定和肾功能正常的肝硬化患者中,应用卡维地洛安全性良好,并可提高生存率。卡维地洛治疗PH的目标剂量为12.5 mg/d。本文就 Baveno Ⅶ推荐在肝硬化中使用卡维地洛的研究进展做一综述。

关键词: 肝硬化, 门静脉高压症, 卡维地洛, 普萘洛尔

陈治莉, 谢青, 莫瑞东. 新型非选择性β受体阻滞剂卡维地洛治疗门静脉高压症的研究进展[J]. 肝脏, 2024, 29(3): 345-347.

参考文献

[1] Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis[J]. Gastroenterology, 2007,133(2):481-488.
[2] Villanueva C, Albillos A, Genesca J, et al. Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension[J]. Hepatology, 2016,63(1):197-206.
[3] Villanueva C, Albillos A, Genescà J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial[J].Lancet, 2019,393(10181):1597-1608.
[4] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno Vll-Renewing consensus in portal hypertension[J]. J Hepatol, 2022,76(4):959-974.
[5] Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol[J]. Gut, 2013,62(11):1634-1641.
[6] Dulin B, Abraham W T. Pharmacology of carvedilol[J]. Am J Cardiol, 2004,93(9A):3B-6B.
[7] Albillos A, Lledo J L, Banares R, et al. Hemodynamic effects of alpha-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension[J]. Hepatology, 1994,20(3):611-617.
[8] Garcia-Pagan J C, Morillas R, Banares R, et al. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT[J]. Hepatology, 2003,37(6):1260-1266.
[9] Bañares R, Moitinho E, Piqueras B, et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis[J]. Hepatology, 1999,30(1):79-83.
[10] Banares R, Moitinho E, Matilla A, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis[J]. Hepatology, 2002,36(6):1367-1373.
[11] Sinagra E, Perricone G, D'Amico M, et al. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis[J]. Aliment Pharmacol Ther,2014,39(6):557-568.
[12] Tripathi D, Therapondos G, Lui H F, et al. Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension[J].Aliment Pharmacol Ther,2002,16(3):373-380.
[13] Schwarzer R, Kivaranovic D, Paternostro R, et al. Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study[J]. Aliment Pharmacol Ther, 2018,47(8):1162-1169.
[14] Groszmann R J, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis[J]. N Engl J Med, 2005,353(21):2254-2261.
[15] Bhardwaj A, Kedarisetty C K, Vashishtha C, et al. Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial[J]. Gut, 2017,66(10):1838-1843.
[16] Mandorfer M, Peck-Radosavljevic M, Reiberger T. Prevention of progression from small to large varices: are we there yet? An updated meta-analysis[J]. Gut, 2017,66(7):1347-1349.
[17] Villanueva C, Torres F, Sarin S K, et al. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis[J]. J Hepatol, 2022,77(4):1014-1025.
[18] Sharma M, Singh S, Desai V, et al. Comparison of therapies for primary prevention of esophageal variceal bleeding: a systematic review and network meta-analysis[J]. Hepatology, 2019,69(4):1657-1675.
[19] Tripathi D, Ferguson J W, Kochar N, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed[J]. Hepatology, 2009,50(3):825-833.
[20] McDowell H R, Chuah C S, Tripathi D, et al. Carvedilol is associated with improved survival in patients with cirrhosis: a long-term follow-up study[J]. Aliment Pharmacol Ther, 2021,53(4):531-539.
[21] Malandris K, Paschos P, Katsoula A, et al. Carvedilol for prevention of variceal bleeding: a systematic review and meta-analysis[J]. Ann Gastroenterol, 2019,32(3):287-297.
[22] Sinha R, Lockman K A, Mallawaarachchi N, et al. Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites[J]. J Hepatol, 2017,67(1):40-46.
[23] Jachs M, Hartl L, Simbrunner B, et al. Carvedilol achieves higher hemodynamic response and lower rebleeding rates than propranolol in secondary prophylaxis[J]. Clin Gastroenterol Hepatol, 2023,21(9):2318-2326.
[24] Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial[J]. JAMA, 2004,292(18):2227-2236.